Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor

A phase I clinical trial in patients with advanced carcinomas was conducted using the orally available neurotrophin receptor-linked tyrosine kinase receptor inhibitor, CEP-701. The objectives were to determine the maximum tolerated dose (MTD), dose-limiting toxicities, and pharmacokinetic profile of...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Investigational new drugs 2005-01, Vol.23 (1), p.31-37
Hauptverfasser:	Marshall, John L, Kindler, Hedy, Deeken, John, Bhargava, Pankaj, Vogelzang, Nicholas J, Rizvi, Naiyer, Luhtala, Taina, Boylan, Stacy, Dordal, Margaret, Robertson, Philmore, Hawkins, Michael J, Ratain, Mark J
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adult Aged Aged, 80 and over Binding sites Blood tests Cancer Cancer therapies Carbazoles - pharmacokinetics Carbazoles - therapeutic use Cell cycle Cell growth Creatinine Dose-Response Relationship, Drug Drug dosages Enzyme Inhibitors - pharmacokinetics Enzyme Inhibitors - therapeutic use Female Humans Indoles - pharmacokinetics Indoles - therapeutic use Kinases Male Maximum Tolerated Dose Middle Aged Neoplasms - blood Neoplasms - drug therapy Patients Pharmacokinetics Prostate Prostate cancer Receptor, trkA - antagonists & inhibitors Thyroid gland Tissues
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!